Dyslipidemia

An analysis of data from the COMPASS study suggests the addition of low-dose rivaroxaban to aspirin resulted in benefits, irrespective of concomitant therapies or comorbidities.

Novartis announced the Complete Response resubmission for inclisiran in a statement on July 6, 2021.

An analysis of data from an RCT suggests statin use does not negatively impact the neurocognitive health or memory of older patients.

The FDA has granted approval to dabigatran etexilate (Pradaxa) for treatment of blood clots in pediatric patients with VTE and prevention of recurrent blood clots in those who have completed treatment for VTE.

Analysis of 2-year data from the GOULD Registry indicates new strategies are needed to address the suboptimal levels of lipid-lowering therapy intensification among patients with ASCVD and increased LDL-C.

The AHA has released a scientific statement highlighting the importance of prescribing physical activity as a first-line treatment in patient populations with elevated blood pressure or elevated cholesterol.

An analysis of patient and clinician responses to surveys within BOAT-AF suggests many were willing to consider DOACs but were never prescribed anticoagulation and also provides insight into how trends in this cohort compared to those in the ACC's PINNACLE registry.

A pooled risk simulation of phase 3 data of bempedoic acid suggests the first-in-class ATP citrate lyase inhibitor could reduce risk of cardiovascular events in patients with established cardiovascular disease and elevated LDL-C.

The TALOS AMI study suggests DAPT de-escalation 30 days after PCI was associated with lower rates of bleeding and the study's composite endpoint of cardiovascular death, MI, or stroke.

As part of our coverage of ACC.21, Practical Cardiology reached out to Deepak Bhatt, MD, MPH, to learn about his reaction to the latest analysis of the STRENGTH trial and how it might impact how REDUCE-IT results are interpreted.

A secondary analysis of the STRENGTH trial from ACC.21 is calling into question the apparent CV benefits of other fish oil-based agents in patients with elevated triglycerides.

The ADAPTABLE study from DCRI suggests patients with existing CVD saw similar outcomes whether they were receiving 81 mg or 325 mg aspirin, but also suggests patients with the higher dose were more likely to discontinue therapy.

The latest study from Penn Medicine's Nudge Unit is detailing the impact of time of appointment on the probability of receiving a prescription for statin therapy at primary care clinics among patients with an indication for statin therapy.

In this column, Dr. Paul Thompson provides an account of a recent conversation with a colleague related to the potential for tendon issues, including tendon rupture, in a patient on statin therapy.

Dr. Paul Thompson reflects on the results of recent N-of-1 studies examining the effects of statin therapy on muscle pain and offers his perspective on the conclusions drawn by these trials.

The American Heart Association and American Stroke Association have released a special report related to the treatment of blood clots or low platelet counts related to the COVID-19 vaccine, which has garnered mass amounts of attention despite being a rare complication.

An SCAI 2021 analysis of more than 4k patients with characteristics similar to those included in the TWILIGHT trial indicates extended-duration DAPT, defined as a duration of more than 12 months post-PCI, was a more efficacious approach than short-term DAPT in this patient population.

A new analysis of claims data performed by clinicians at Penn Medicine suggests less than 1% of patients with ASCVD initiated therapy with a PCKS9 inhibitor from 2015-2019.

A case-controlled study of patients in the PREVEND study indicates HDL anti-inflammatory capacity could help identify patients at a greater risk of cardiovascular disease.

In the final portion of this video series, panelists discuss the implementation and use of telehealth in cardiology, but specifically the management of cholesterol disorders.

In this portion of the panel discussion, panelists examine newer therapies for the treatment of lipid disorders. Included in this section are brief discussions around icosapent ethyl, inclisiran, and bempedoic acid. *This conversation occurred in February 2021 and regulatory approvals/decisions may have changed since filming.

In this edition of Inside Cardiology, a trio of advisory board members discuss a series of case reports, upcoming and newly released therapies for lipid disorders, and use of telehealth for the management of patients.

Welcome to Inside Cardiology: Lipid Management 2021. This edition of Inside Cardiology features a discussion around lipidology led by Chief of Practical Cardiology's Editorial Advisory Board Guy Mintz, MD. Mintz is joined by fellow advisory board members Lucia Novak, CRNP, and Brett Nowlan, MD. In the first segment, panelists introduce themselves and examine the first case report in their 5-part discussion.

In this segment, panelists discuss their third and final case report. This case features a 63-year-old male classified as a very high-risk patient.

In this segment, panelists discuss their second case report. This case features a 60-year-old female classified as an extreme risk patient with diabetes.

Althera Pharmaceuticals announced the FDA approved rosuvastatin and ezetimibe (Roszet) as an adjunct to diet for lowering LDL-C in adults patients with primary non-familial hyperlipidemia or homozygous familial hypercholesterolemia.

Announced in a statement by the FDA on April 1, the PCKS9 inhibitor alirocumab is now indicated as an add-on therapy for the treatment of homozygous familial hypercholesterolemia.

In this column, Arnold Meshkov, MD, explores the history of the "Thrombus Hypothesis" and his experiences with thrombus in myocardial infarction as a practicing clinician.

An analysis comparing propensity-matched data from 4k transgender is providing an updated overview of the risk profile for patients undergoing gender-affirming therapy compared to their cisgender counterparts.

An analysis of the REDUCE-IT trial suggests patients on statins who were also receiving icosapent ethyl reduced their risk of an ischemic stroke by an additional 36%.